search
diabetes patients
Trends
- 1One Genetic Tweak Could Turn Pancreatic Cells Into Diabetes Treatment▼Some Pancreatic Cells Are Just One Genetic Tweak Away From Treating Diabetes https:// fed.brid.gy/r/https://www.wire d.c
A Wired report describes new research suggesting certain pancreatic cells can be converted into insulin-producing beta cells with a single genetic modification, offering a potential new avenue for treating diabetes. Scientists say the finding could eventually help restore insulin production in patients, though it remains at an early stage.
- 2Stopping GLP-1 drugs may raise heart attack and stroke risk●Stopping GLP-1 drugs may raise heart attack and stroke risk, study finds
A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.
- 3Diabetes Study Suggests Overly Steady Blood Sugar Has Costs▼Diabetes study finds keeping blood sugar too steady may come at a price
A new diabetes study reports that keeping blood sugar extremely steady may come at a price, challenging the assumption that tighter, more consistent glucose control is always better for patients. The findings are drawing attention from clinicians and people managing diabetes, as they raise questions about how aggressively blood sugar fluctuations should be smoothed out in day-to-day treatment and what trade-offs strict control may involve.
- 4Israeli startup DreaMed wins FDA nod for insulin-dosing app▼Israeli startup DreaMed gets FDA approval for app that adjusts insulin doses for Type 2 diabetes
Israeli medtech startup DreaMed Diabetes has received FDA approval for an app that automatically adjusts insulin doses for people with Type 2 diabetes. The clearance lets the company bring its digital insulin-management tool to American patients, extending technology previously aimed at Type 1 diabetes. The news, reported by Calcalist, is being read as a milestone for Israeli digital health firms seeking US market entry.
- 5Doctors weigh in on the Ozempic microdosing trend▼Is microdosing Ozempic safe? An obesity medicine doctor on the trend, the risks, and when a low dose makes sense
An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.
- 6Israeli startup wins FDA clearance for injection-based diabetes app▼Israeli startup develops injection-based diabetes app, receives FDA clearance
An Israeli startup has received FDA clearance for an app designed to support people who manage diabetes with insulin injections. The digital tool aims to help patients track and manage their injection-based treatment, and its clearance means it can now be marketed in the United States. The news was reported by The Jerusalem Post and highlights Israel's growing health-tech sector.
- 7Doctors warn GLP-1 drug users face heat wave health risks▼Amid heat wave, doctors warn of health risks for people taking GLP-1 drugs
Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic may face heightened health risks during the current heat wave. Concerns center on dehydration, as the medications can suppress thirst and appetite, potentially leaving users vulnerable to heat exhaustion and related complications. Patients are being advised to drink water regularly and take precautions in high temperatures as extreme heat persists across many regions.
- 8FDA approves Onswik, a once-weekly insulin for type 2 diabetes●The FDA approved Onswik, a once-weekly insulin for type 2 diabetes, but not for type 1. What the trials showed and the s
The FDA has approved Onswik, a once-weekly insulin intended for adults with type 2 diabetes. It was not approved for type 1 diabetes. Coverage highlights what the clinical trials showed about effectiveness and the side effects patients should know about. The approval is drawing attention as a potential convenience shift for diabetes management, reducing injections from daily to weekly.
- 9Study links GLP-1 drugs in children to nutritional deficiencies●Interactive: Study links GLP-1 use in children to nutritional deficiencies
A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.
- 10Heart and Kidney Problems Rise Over Time in Type 2 Diabetes▼Heart and Kidney Problems in Type 2 Diabetes Patients Increase with Time
New coverage reports that heart and kidney complications in patients with type 2 diabetes increase as the disease progresses over time. The finding underscores the cumulative toll of diabetes on cardiovascular and renal health and highlights the importance of long-term monitoring and management of blood sugar, blood pressure and kidney function in affected patients.